FDA approval, Breakthrough Therapy status and an early Alzheimer’s trial reshape Arrowhead Pharmaceuticals’ outlook.
California-based biotech Arrowhead Pharmaceuticals has quietly become one of 2025’s most dramatic biotech turnaround stories. Long known as a “next-year” RNA interference (RNAi) company, Arrowhead now has what investors have waited years to see: an FDA-approved drug, expanding regulatory momentum and a pipeline that reaches beyond rare disease into far larger metabolic and neurological markets.
As of 11 December 2025, Arrowhead’s stock was trading at about $70 per share, after briefly rising above $72 earlier in the day – its highest level in the past year. The increase has been rapid. Just a month ago, the stock was priced in the low $40s, meaning its value has jumped sharply in a short period. As a result, the company’s total value has grown more than threefold since a year ago.
The rally has been volatile, with sharp pullbacks and rebounds along the way, but it reflects a more profound shift in Arrowhead’s fundamentals rather than a single speculative spike.
The most crucial catalyst came on 18 November, when the US Food and Drug Administration (FDA) approved Redemplo (plozasiran) for adults with familial chylomicronemia syndrome (FCS), an ultra-rare genetic disorder marked by extremely high triglyceride levels and recurrent pancreatitis [1].
In a large clinical trial, the drug dramatically lowered dangerous fat levels in the blood. It significantly reduced the risk of painful, potentially life-threatening pancreas attacks compared with a dummy treatment.
While the condition it treats is very rare – affecting only a few thousand people worldwide – analysts still expect strong sales because treatments for rare diseases are typically priced at a premium. Some estimates suggest the drug could generate more than $1 billion in annual sales by the early 2030s.
For investors, the approval matters less for near-term revenue and more for what it signals. Regulators have now validated Arrowhead’s core RNAi chemistry in a commercial setting, de-risking the platform and giving the company its first recurring product revenue stream. Arrowhead has also partnered with Sanofi on Greater China rights to Redemplo, extending its global reach [2].
Just weeks after the FCS approval, the FDA granted Breakthrough Therapy designation to plozasiran for severe hypertriglyceridemia (SHTG), defined as triglyceride levels of at least 500 mg/dL. Unlike FCS, SHTG affects millions of people worldwide and carries elevated cardiovascular and pancreatitis risk.
The designation is designed to speed development and review for therapies that may offer substantial improvement over existing options.
Arrowhead is currently running two Phase 3 trials, involving people with different types of dangerously high blood fat levels. The company expects to complete these studies by mid-2026 and then seek regulatory approval to expand the drug’s approved uses before the end of that year.
If successful, plozasiran could move from an ultra-rare indication into a much broader cardiometabolic population, fundamentally changing Arrowhead’s revenue potential.
Arrowhead’s ambitions now extend beyond the liver. On 8 December, the company announced that it had dosed the first patients in a Phase 1/2a trial of ARO-MAPT, an investigational RNAi therapy targeting tau in Alzheimer’s disease and other tauopathies [3].
The news sent the stock sharply higher intraday. ARO-MAPT is notable because it uses a new proprietary delivery system designed to cross the blood–brain barrier after a subcutaneous injection, a longstanding challenge in neurology drug development.
Preclinical studies showed deep gene knockdown across the central nervous system, including deep brain regions.
Whether this translates into human benefit remains an open question, but the trial signals that Arrowhead intends to push its RNAi platform well beyond traditional liver-focused indications.
Another major driver of Arrowhead’s resurgence has been cash from large pharmaceutical partners. In September, the company licensed a neuromuscular RNAi program to Novartis in a deal worth up to $2 billion, including $200 million upfront. It also received a $200 million milestone payment from Sarepta late in the year. These deals transformed Arrowhead’s financials.
Analysts are mostly positive on Arrowhead, raising their price predictions. Some now see the stock reaching $80–$85, while older estimates still linger around $58–$62. The gap reflects how quickly the stock has risen in recent weeks, leaving some forecasts behind.
That gap underscores both optimism and risk. Arrowhead is now valued as a mid-cap commercial-stage biotech, not a speculative platform story.
Despite the momentum, Arrowhead remains a high-risk investment. The stock is prone to sharp swings, patent litigation with Ionis over RNAi technology remains unresolved, and clinical outcomes in larger metabolic populations and in Alzheimer’s disease are far from guaranteed.
The company has also filed a mixed shelf registration, giving it flexibility to raise capital but raising the prospect of dilution.
Arrowhead has crossed a crucial threshold. With an FDA-approved drug, expanding late-stage programs and a validated RNAi platform attracting deep-pocketed partners, it has moved firmly onto biotech’s main stage. For investors, the question is no longer whether the science works in principle, but how far and how profitably it can scale.
[1] https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-announces-fda-approval-redemplor
[2] https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-subsidiary-visirna-sells-rights-hypertriglyceridemia
[3] https://arrowheadpharma.com/news-press/arrowhead-pharmaceuticals-initiates-phase-1-2a-study-of-aro-mapt-for-the-treatment-of-alzheimers-disease-and-other-tauopathies/
